Alpha Tau Medical Ltd./$DRTS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
- Ticker
- $DRTS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 121
- Headquarters
- Jerusalem, Israel
- Website
- www.alphatau.com
DRTS Metrics
BasicAdvanced
$1.3B
-
-$1.05
1.18
-
Price and volume
Market cap
$1.3B
Beta
1.18
52-week high
$15.79
52-week low
$3.43
Average daily volume
493K
Financial strength
Current ratio
11.091
Quick ratio
10.448
Long term debt to equity
0.314
Total debt to equity
0.344
Interest coverage (TTM)
-140.08%
Profitability
EBITDA (TTM)
-48.76
Effective tax rate (TTM)
-0.19%
Management effectiveness
Return on assets (TTM)
-25.71%
Return on equity (TTM)
-141.68%
Valuation
Price to book
29.38
Price to tangible book (TTM)
29.38
Price to free cash flow (TTM)
-76.582
Free cash flow yield (TTM)
-1.31%
Free cash flow per share (TTM)
-0.183
Growth
Earnings per share change (TTM)
117.36%
3-year earnings per share growth (CAGR)
47.00%
What the Analysts think about DRTS
Analyst ratings (Buy, Hold, Sell) for Alpha Tau Medical Ltd. stock.
Analyst projections of the future price of Alpha Tau Medical Ltd. stock.
Bulls say / Bears say
In recurrent glioblastoma, interim results in the first three patients showed local disease control in all three and complete responses in two; the FDA has since allowed the trial to expand to 20 patients. This is a promising early signal in a cancer with few treatment options. (Alpha Tau Medical, Alpha Tau Medical)
In a head and neck cancer study, all nine evaluable patients responded to Alpha DaRT plus pembrolizumab, with median overall survival of 18.2 months. The result met the study’s pre-set success threshold and offers another promising clinical signal. (Alpha Tau Medical)
Tolmar has partnered with Alpha Tau on US prostate cancer development and commercialisation, investing $20 million and contributing $15 million towards manufacturing capacity. The agreement also provides for up to $161.5 million in development, regulatory and commercial milestone payments. (Alpha Tau Medical)
The strongest results so far come from small, uncontrolled studies: only nine head and neck patients were evaluable, and the survival comparison was against historical data rather than a randomised control group. The company itself cautions that results from separate studies are not directly comparable. (Alpha Tau Medical)
The Tolmar partnership does not secure near-term US sales: its filing says Alpha DaRT cannot be marketed or sold there before FDA approval. Regulatory progress is therefore still a key hurdle to turning the deal into product revenue. (Stock Titan)
Alpha Tau says it has yet to generate revenue, expects losses for several more years and may need substantial additional funding. Further fundraising could dilute existing shareholders before the business reaches commercial scale. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
DRTS Financial Performance
Revenues and expenses
DRTS Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing DRTS
Fund name | Fund size | $DRTS weighting |
|---|---|---|
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.